ERBB2 and neoplasm: Since tyrosine kinase activation is the downstream mechanism of action for Her-2/neu, it has been postulated that tumours exhibiting active Her-2/neu signalling represented by phosphorylation of tyrosine residues might be those most sensitive to treatment with trastuzumab (DiGiovanna and Stern, 1995; Thor et al, 2000).